Deerfield Management portfolio
Concentrated managerInvestment firmPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Deerfield Management reported a $8.0 bn portfolio of 70 companies (72 positions, counting each share class separately) to the SEC as of the end of Q2 2026. Its largest positions are Nuvalent, RVMD, PRAX. During the quarter it opened Mineralys Therapeutics and Boston Scientific and exited Catalyst Pharmaceuticals and Neurocrine Biosciences.
Sections with a free account
What changed this quarter
37 positions with a change (5 new, 12 added to, 11 trimmed, 9 sold); also, 4 entered through an IPO, 3 exited through an acquisition or merger, 2 entered through a spin-off. 11 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Newly listedParabilis MedicinesPBLS0.6% of the portfolio
It started trading this quarter: it appears in a 13F for the first time. The filing does not say whether the manager already held it before the listing, so it is not counted as a purchase.
- Cogent Biosciences−45%fewer sharesReduced4.9% → 2.4%
- Genmab A/S+179%more sharesIncreased0.9% → 2.3%
- Mineralys Therapeutics+1.3 ppof portfolioNew— → 1.3%
- Catalyst Pharmaceuticals−1.2 ppof portfolioSold out1.4% → —
- Neurocrine Biosciences−1.0 ppof portfolioSold out1.1% → —
- Centene−17%fewer sharesReduced2.7% → 3.9%
- Inspire Medical Systems−52%fewer sharesReduced1.9% → 0.7%
- Indivior Pharmaceuticals−47%fewer sharesReduced1.3% → 0.8%
- Boston Scientific+0.7 ppof portfolioNew— → 0.7%
- Kymera Therapeutics−0.6 ppof portfolioSold out0.7% → —
- IDEAYA Biosciences+77%more sharesIncreased0.7% → 1.3%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Nuvalent26.5%
- Revolution MedicinesRVMD5.6%
- Praxis Precision MedicinesPRAX4.0%
- ViatrisVTRS4.0%
- CenteneCNC3.9%
- United TherapeuticsUTHR3.1%
- Legend BiotechLEGN2.9%
- Cogent BiosciencesCOGT2.4%
- Genmab A/SGMAB2.3%
- Brookdale Senior LivingBKD2.3%
- Vera TherapeuticsVERA2.1%
- Ionis PharmaceuticalsIONS2.0%
- CelcuityCELC1.9%
- Biocryst PharmaceuticalsBCRX1.9%
- NewAmsterdam PharmaNAMS · NAMSW1.8%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 99%
- ● Information Technology 1%
How its portfolio changed (8 quarters)
Q2 2026: 72
Q2 2026: 57%
Q2 2026: 8.0%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Investment firm, per its Form ADV of Jul 31, 2026 (high confidence).
The data, as reported: DEERFIELD MANAGEMENT COMPANY (CRD 157876): 7.B private funds: 11 hedge, 1 pe (gross assets $19.2 bn); 5.D assets by client type: pooled vehicles 100% (of $19.1 bn)
The type comes from a rule applied to that data. If it looks wrong, tell us.
Similar managers by type and size
Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.
- First Pacific AdvisorsInvestment firm · $8.0 bn
- Greenhaven AssociatesInvestment firm · $8.0 bn
- Lyrical Asset ManagementInvestment firm · $7.9 bn
- Carl C IcahnInvestment firm · $8.3 bn
- Carmignac GestionInvestment firm · $7.7 bn
- Yacktman Asset ManagementInvestment firm · $8.4 bn